OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ovid Therapeutics Inc is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite bullish technical indicators and positive analyst updates, the lack of recent news, insider and hedge fund selling, and weak financial performance in the latest quarter suggest caution. The stock may be better suited for speculative traders rather than long-term investors.
The technical indicators show a bullish trend with MACD above 0 and positively contracting, RSI in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 2.301, with resistance at 2.62 and support at 1.982.
Analysts have raised price targets significantly, with Wedbush increasing it to $7 and Roth Capital to $5, citing positive developments in the OV329 program and upcoming R&D events.
Hedge funds and insiders are selling heavily, with hedge fund selling up 668.25% and insider selling up 228.75%. Additionally, the pre-market price is down 2.03%, and financial performance shows a significant drop in net income and EPS.
In 2025/Q4, revenue increased by 844.74% YoY to $718,000, but net income dropped by -204.43% YoY to -$9,663,000, and EPS fell by -192.31% YoY to 0.12. Gross margin remained at 100%.
Analysts are optimistic, with Wedbush and Roth Capital raising price targets and maintaining Outperform and Buy ratings, respectively. Positive updates on OV329 and KCC2 efforts are highlighted.
